NICE Technology Appraisal 607: Rivaroxaban for preventing atherothrombotic events in people with coronary or peripheral artery disease
The production of this Guidelines card has been commissioned by Bayer plc. Bayer plc has reviewed the card for technical accuracy and regulatory compliance and supplied the prescribing information.
Real-world evidence in the management of type 2 diabetes: switching from other DPP‑4 inhibitors to alogliptin (Vipidia®)
This promotional educational webinar has been organised and funded by Takeda UK Ltd. See bottom of page for full disclaimer.